Inventor · disambiguated record
Brett B. Busch
Also filed as: BUSCH BRETT · BUSCH BRETT B · BUSCH BRETT BRADLEY
14 granted patents·12 pending applications·136 citations·filing 2003–2024
92Inventor score
Top patents by PatentIndex Score
26 records- 0196US10570115B2Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulatorVERTEX PHARMA·Filed 2017·Granted Feb 25, 2020·23 cites·18 claims
- 0295US11066417B2Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulatorsVERTEX PHARMA·Filed 2019·Granted Jul 20, 2021·13 cites·47 claims
- 0394US11866450B2Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulatorsVERTEX PHARMA·Filed 2021·Granted Jan 9, 2024·3 cites·41 claims
- 0492US11186566B2Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulatorVERTEX PHARMA·Filed 2019·Granted Nov 30, 2021·10 cites·10 claims
- 0591US7998995B2LXR and FXR modulatorsEXELIXIS PATENT CO LLC·Filed 2007·Granted Aug 16, 2011·32 cites·45 claims
- 0687US7595311B2Azepinoindole derivatives as pharmaceutical agentsEXELIXIS INC·Filed 2003·Granted Sep 29, 2009·29 cites·63 claims
- 0786US8703805B2Modulators of LXRBUSCH BRETT B·Filed 2006·Granted Apr 22, 2014·11 cites·41 claims
- 0882US9000022B2Imidazole based LXR modulatorsEXELIXIS PATENT CO LLC·Filed 2013·Granted Apr 7, 2015·6 cites·15 claims
- 0982US8618154B2LXR modulatorsBUSCH BRETT B·Filed 2010·Granted Dec 31, 2013·6 cites·30 claims
- 1078US8569352B2Imidazole based LXR modulatorsBUSCH BRETT B·Filed 2006·Granted Oct 29, 2013·3 cites·31 claims
- 1178US2024368189A1Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the ModulatorsVERTEX PHARMA·Filed 2023·Application pending·0 cites
- 1271US12258332B2ASGPR cell surface receptor binding compounds and conjugatesLYCIA THERAPEUTICS INC·Filed 2023·Granted Mar 25, 2025·0 cites·18 claims
- 1371US2022306606A1Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulatorVERTEX PHARMA·Filed 2021·Application pending·0 cites
- 1471US2025101007A1Asgpr cell surface receptor binding compounds and conjugatesLYCIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1559US8524704B2Azepinoindole derivatives as pharmaceutical agentsBUSCH BRETT·Filed 2009·Granted Sep 3, 2013·0 cites·24 claims
- 1658US2014163081A1Lxr modulatorsEXELIXIS PATENT CO LLC·Filed 2013·Application pending·0 cites
- 1755US2024335544A1M6pr cell surface receptor binding compounds and conjugatesLYCIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1854US2023234943A1Trex1 inhibitors and uses thereofTEMPEST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1953US2024165250A1Bifunctional Folate Receptor Binding CompoundsLYCIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2053US2016280661A1Lxr modulatorsEXELIXIS PATENT CO LLC·Filed 2016·Application pending·0 cites
- 2150US2015299136A1Lxr modulatorsBRISTOL MYERS SQUIBB CO·Filed 2015·Application pending·0 cites
- 2250US2022313698A1Modulators of cystic fibrosis transmembrane conductance regulatorVERTEX PHARMA·Filed 2020·Application pending·0 cites
- 2348US2023158155A1Cell Surface Receptor Binding Compounds and ConjugatesLYCIA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2444US2009203577A1Azepinoindole Derivatives As Pharmaceutical AgentsEXELIXIS INC·Filed 2006·Application pending·0 cites
- 2543US7977489B2Benzylthiazolone inhibitors of estrogen-related receptors (ERR)EXELIXIS INC·Filed 2005·Granted Jul 12, 2011·0 cites·61 claims
- 2637US9751869B2LXR modulatorsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Sep 5, 2017·0 cites·19 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →